Close Menu

cancer sequencing

Researchers participating in ORIEN's Avatar program can use the platform to manage, share, integrate, and analyze molecular data from consenting patients.

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

The company recently released an RUO RNA extraction kit, and plans to launch a liquid biopsy pan-cancer test and disease-specific NGS panels later this year.

Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.

The company reported 8,985 clinical tests in the first quarter, a 14 percent year-over-year increase.

The firm's $80 investment in Lasergen sets the stage for it to develop an integrated sample-to-result clinical genomics workflow by 2020.

The Wellcome Trust Sanger Institute spinout was working on combining genomic and clinical data sets to inform cancer diagnosis, prognosis, and treatment.

These are exciting times in oncology, but community oncologists need support to keep up with rapidly advancing science, said Lincoln Nadauld.

The study, which will be the pediatric counterpart to the ongoing adult-only NCI-MATCH trial, will be run by the NCI in partnership with the Children's Oncology Group.

The funds from the Sohn Conference Foundation will allow the university to provide sequencing analysis and expertise to kids with cancer to hospitals in the city.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.